Viatris (XTER:VIA) Other Current Liabilities : €1,168 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viatris Other Current Liabilities?

Viatris's other current liabilities for the quarter that ended in Mar. 2024 was €1,168 Mil.

Viatris's quarterly other current liabilities increased from Sep. 2023 (€983 Mil) to Dec. 2023 (€1,268 Mil) but then declined from Dec. 2023 (€1,268 Mil) to Mar. 2024 (€1,168 Mil).

Viatris's annual other current liabilities declined from Dec. 2021 (€1,248 Mil) to Dec. 2022 (€1,169 Mil) but then increased from Dec. 2022 (€1,169 Mil) to Dec. 2023 (€1,268 Mil).

Viatris Other Current Liabilities Historical Data

The historical data trend for Viatris's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Other Current Liabilities Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Viatris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Viatris Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Viatris Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Viatris's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (XTER:VIA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (XTER:VIA) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.